154 related articles for article (PubMed ID: 9495360)
1. p16/MTS1 inactivation in ovarian carcinomas: high frequency of reduced protein expression associated with hyper-methylation or mutation in endometrioid and mucinous tumors.
Milde-Langosch K; Ocon E; Becker G; Löning T
Int J Cancer; 1998 Feb; 79(1):61-5. PubMed ID: 9495360
[TBL] [Abstract][Full Text] [Related]
2. Inactivation of p16/CDKN2 and p15/MTS2 genes in different histological types and clinical stages of primary ovarian tumors.
Ichikawa Y; Yoshida S; Koyama Y; Hirai M; Ishikawa T; Nishida M; Tsunoda H; Kubo T; Miwa M; Uchida K
Int J Cancer; 1996 Dec; 69(6):466-70. PubMed ID: 8980248
[TBL] [Abstract][Full Text] [Related]
3. Characterization of chromosome 9 in human ovarian neoplasia identifies frequent genetic imbalance on 9q and rare alterations involving 9p, including CDKN2.
Schultz DC; Vanderveer L; Buetow KH; Boente MP; Ozols RF; Hamilton TC; Godwin AK
Cancer Res; 1995 May; 55(10):2150-7. PubMed ID: 7743516
[TBL] [Abstract][Full Text] [Related]
4. Alteration of p16 and p15 genes in common epithelial ovarian tumors.
Fujita M; Enomoto T; Haba T; Nakashima R; Sasaki M; Yoshino K; Wada H; Buzard GS; Matsuzaki N; Wakasa K; Murata Y
Int J Cancer; 1997 Apr; 74(2):148-55. PubMed ID: 9133447
[TBL] [Abstract][Full Text] [Related]
5. Absence of deletions but frequent loss of expression of p16INK4 in human ovarian tumours.
Marchini S; Codegoni AM; Bonazzi C; Chiari S; Broggini M
Br J Cancer; 1997; 76(2):146-9. PubMed ID: 9231912
[TBL] [Abstract][Full Text] [Related]
6. Alteration of the p53 tumor suppressor gene occurs independently of K-ras activation and more frequently in serous adenocarcinomas than in other common epithelial tumors of the human ovary.
Fujita M; Enomoto T; Inoue M; Tanizawa O; Ozaki M; Rice JM; Nomura T
Jpn J Cancer Res; 1994 Dec; 85(12):1247-56. PubMed ID: 7852189
[TBL] [Abstract][Full Text] [Related]
7. p16(CDKN2) gene polymorphism: association with histologic subtypes of epithelial ovarian cancer in China.
Yan L; Na W; Shan K; Xiao-Wei M; Wei G; Shu-Cheng C
Int J Gynecol Cancer; 2008; 18(1):30-5. PubMed ID: 17466040
[TBL] [Abstract][Full Text] [Related]
8. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors.
Obata K; Morland SJ; Watson RH; Hitchcock A; Chenevix-Trench G; Thomas EJ; Campbell IG
Cancer Res; 1998 May; 58(10):2095-7. PubMed ID: 9605750
[TBL] [Abstract][Full Text] [Related]
9. No evidence exists for methylation inactivation of the p16 tumor suppressor gene in ovarian carcinogenesis.
Ryan A; Al-Jehani RM; Mulligan KT; Jacobs IJ
Gynecol Oncol; 1998 Jan; 68(1):14-7. PubMed ID: 9454653
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical p16INK4a analysis of archival tumors with deletion, hypermethylation, or mutation of the CDKN2/MTS1 gene. A comparison of four commercial antibodies.
Geradts J; Hruban RH; Schutte M; Kern SE; Maynard R
Appl Immunohistochem Mol Morphol; 2000 Mar; 8(1):71-9. PubMed ID: 10937052
[TBL] [Abstract][Full Text] [Related]
11. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers.
Herman JG; Merlo A; Mao L; Lapidus RG; Issa JP; Davidson NE; Sidransky D; Baylin SB
Cancer Res; 1995 Oct; 55(20):4525-30. PubMed ID: 7553621
[TBL] [Abstract][Full Text] [Related]
12. p16 expression in primary ovarian mucinous and endometrioid tumors and metastatic adenocarcinomas in the ovary: utility for identification of metastatic HPV-related endocervical adenocarcinomas.
Vang R; Gown AM; Farinola M; Barry TS; Wheeler DT; Yemelyanova A; Seidman JD; Judson K; Ronnett BM
Am J Surg Pathol; 2007 May; 31(5):653-63. PubMed ID: 17460447
[TBL] [Abstract][Full Text] [Related]
13. Promoter hypermethylation contributes to frequent inactivation of a putative conditional tumor suppressor gene connective tissue growth factor in ovarian cancer.
Kikuchi R; Tsuda H; Kanai Y; Kasamatsu T; Sengoku K; Hirohashi S; Inazawa J; Imoto I
Cancer Res; 2007 Aug; 67(15):7095-105. PubMed ID: 17671176
[TBL] [Abstract][Full Text] [Related]
14. Inactivation of the INK4a/ARF locus and p53 in sporadic extrahepatic bile duct cancers and bile tract cancer cell lines.
Caca K; Feisthammel J; Klee K; Tannapfel A; Witzigmann H; Wittekind C; Mössner J; Berr F
Int J Cancer; 2002 Feb; 97(4):481-8. PubMed ID: 11802210
[TBL] [Abstract][Full Text] [Related]
15. INK4a-ARF alterations and p53 mutations in hepatocellular carcinomas.
Tannapfel A; Busse C; Weinans L; Benicke M; Katalinic A; Geissler F; Hauss J; Wittekind C
Oncogene; 2001 Oct; 20(48):7104-9. PubMed ID: 11704835
[TBL] [Abstract][Full Text] [Related]
16. Preferential loss of expression of p16(INK4a) rather than p19(ARF) in breast cancer.
Brenner AJ; Paladugu A; Wang H; Olopade OI; Dreyling MH; Aldaz CM
Clin Cancer Res; 1996 Dec; 2(12):1993-8. PubMed ID: 9816158
[TBL] [Abstract][Full Text] [Related]
17. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
[TBL] [Abstract][Full Text] [Related]
18. Genetic alterations in gastrinomas and nonfunctioning pancreatic neuroendocrine tumors: an analysis of p16/MTS1 tumor suppressor gene inactivation.
Muscarella P; Melvin WS; Fisher WE; Foor J; Ellison EC; Herman JG; Schirmer WJ; Hitchcock CL; DeYoung BR; Weghorst CM
Cancer Res; 1998 Jan; 58(2):237-40. PubMed ID: 9443399
[TBL] [Abstract][Full Text] [Related]
19. Alterations of p16INK4A and p15INK4B genes in gastric carcinomas.
Lee YY; Kang SH; Seo JY; Jung CW; Lee KU; Choe KJ; Kim BK; Kim NK; Koeffler HP; Bang YJ
Cancer; 1997 Nov; 80(10):1889-96. PubMed ID: 9366289
[TBL] [Abstract][Full Text] [Related]
20. High frequency of p16INK4A gene alterations in hepatocellular carcinoma.
Liew CT; Li HM; Lo KW; Leow CK; Chan JY; Hin LY; Lau WY; Lai PB; Lim BK; Huang J; Leung WT; Wu S; Lee JC
Oncogene; 1999 Jan; 18(3):789-95. PubMed ID: 9989830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
